Clinical trials: Advanced Hepatocellular Carcinoma (HCC), open to volunteers
Advanced Hepatocellular Carcinoma, Atezolizumab
dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma
This study intends to evaluate the efficacy and safety of drug-eluting transcatheter arterial embolization-hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin (dTACE-HAIC) plus Bevacizumab and…
- Conditions
- Advanced Hepatocellular Carcinoma, Atezolizumab, Bevacizumab, Chemotherapy
- Trial name
- NCT06609863
- Testing
- dTACE-HAIC
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Sun Yat-sen University
NSCLC, Prostate Cancer
Clinical Trial of TB511 in Advanced Solid Tumors
1. Study population [TB511 Monotherapy Cohort for Phase 1 and Phase 2a Clinical Trial] Patients with advanced solid tumors who are either refractory or intolerant to standard of care (SoC).
- Conditions
- NSCLC, Prostate Cancer, Colorectal Cancer, Hepatocellular Carcinoma
- Trial name
- NCT06400160
- Testing
- TB511, Keytruda
- Volunteers
- 12 people
- Sponsor
- Twinpig Biolab, Inc.
Advanced Hepatocellular Carcinoma
A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
This study is a clinical study to explore the efficacy and safety of BL-B01D1 monotherapy, BL-B01D1 in combination with lenvatinib, BL-B01D1 in combination with PD-1 monoclonal antibody, and BL-B01D1 in combination with PD-1…
- Trial name
- NCT06986785
- Testing
- BL-B01D1, Lenvatinib, Finotonlimab
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE)…
- Trial name
- NCT06600321
- Testing
- ALN-BCAT, Pembrolizumab
- Where
- 23 sites in United States, Italy and 1 more
- Volunteers
- 158 people
- Sponsor
- Alnylam Pharmaceuticals
Advanced Hepatocellular Carcinoma, Oligometastasis
Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma
Ablation has been an effective approach for treating intrathoracic metastases. However, for hepatocellular carcinoma with oligometastasis, ablation of metastases remains relatively unexplored.
- Conditions
- Advanced Hepatocellular Carcinoma, Oligometastasis, Ablation, Anti-PD1 Antibody
- Trial name
- NCT06550921
- Testing
- ablation of oligometastasis
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Solid Tumor Cancer, Adult Refractory Cancer
Study of GV20-0251 in Participants With Solid Tumor Malignancies
This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT07070518
- Testing
- GV20-0251
- Where
- 3 sites in China
- Volunteers
- 350 people
- Sponsor
- GV20 Therapeutics
Cancer, Cancer (Solid Tumors)
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
The goal of this clinical trial is to test JMT108, a type of drug called a bispecific antibody in adult patients with locally advanced or metastatic solid tumors.
- Trial name
- NCT07317505
- Testing
- JMT108
- Where
- 3 sites in United States
- Volunteers
- 270 people
- Sponsor
- Conjupro Biotherapeutics, Inc.
Hepatocellular Carcinoma (HCC), Real World Study
The Efficacy and Safety of First-line Treatment Combined With Immunotherapy for Advanced Hepatocellular Carcinoma: a Single Center, Real-world Study
In recent years, immunotherapy represented by PD-1/PD-L1 inhibitors has continuously brought breakthroughs in the treatment of hepatocellular carcinoma and has gradually become the cornerstone of advanced liver cancer treatment.
- Trial name
- NCT07078292
- Volunteers
- 400 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Hepatocellular Carcinoma
A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma
To evaluate the efficacy and safety of TAE+HAIC combined with camrelizumab and apatinib in the treatment of advanced liver cancer with high tumor load
- Trial name
- NCT06363825
- Testing
- camrelizumab
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Fujian Medical University
Hepatocellular Carcinoma
Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma With Localized Portal Vein Tumor Thrombosis
The RESOLVE trial, an open-label, single-arm, multi-center study, aims to assess the efficacy and safety of ablative radioembolization using TheraSphere Yttrium-90 microspheres.
- Trial name
- RESOLVE (NCT06166576)
- Testing
- Ablative radioembolization
- Where
- 5 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- Seoul National University Hospital
Advanced Hepatocellular Carcinoma
SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)
This is a phase 3, multicentri, randomised, open label study. The purpose is to investigate the safety and efficacy of stereotactic body radiation therapy (SBRT) combined with transarterial chemoembolization (TACE) and lenvatinib…
- Trial name
- SEARCH (NCT05718232)
- Testing
- Lenvatinib, TACE, SBRT
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma (HCC)
Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer
This study is for people with unresectable or advanced hepatocellular carcinoma who have not received previous systemic treatment for liver cancer. The study will compare lenvatinib plus tislelizumab with or without gefitinib.
- Trial name
- LENTIG-HCC (NCT07829926)
- Testing
- Lenvatinib, Tislelizumab, Gefitinib
- Volunteers
- 120 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine
Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome
Primary liver cancer is a malignant tumor with a very poor prognosis. Hepatocellular carcinoma(HCC) accounts for approximately 80% of cases.
- Conditions
- HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine, ICG (Indocyanine Green), Overall Survival (All-cause Mortality)
- Trial name
- DAWNbreak-120 (NCT07691645)
- Testing
- Shuganhuazhuo Formula, Targeted therapy, Immunotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xiang-Qian
Solid Tumor, Non-small Cell Lung Cancer
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT07623369
- Testing
- HH160
- Where
- 3 sites in Australia, China
- Volunteers
- 299 people
- Sponsor
- Huahui Health
Hepatocellular Carcinoma, Atezolizumab-bevacizumab
Ate-Bev Early Response Prediction Model in Advanced HCC
The prognosis of hepatocellular carcinoma is poor compared to other carcinomas. Many drugs have recently been developed, and recently, atezolizumab-bevacizumab treatment was superior to sorafenib, the conventional treatment for…
- Conditions
- Hepatocellular Carcinoma, Atezolizumab-bevacizumab, Response Evaluation
- Trial name
- NCT05763277
- Testing
- Early response evaluation
- Where
- South Korea
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Advanced Solid Tumors, Ewing Sarcoma
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies
- Conditions
- Advanced Solid Tumors, Ewing Sarcoma, Hepatocellular Carcinoma (HCC), Biliary Tract Cancer (BTC)
- Trial name
- NCT07197554
- Testing
- ST-01156
- Where
- 6 sites in United States
- Volunteers
- 171 people
- Sponsor
- SEED Therapeutics, Inc.
Hepatocellular Carcinoma, Liver Cancer, Adult
Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC
This is an open-label and multi-center Phase 2 study to evaluate the safety and efficacy of autologous T-cells transfected with mRNA encoding Hepatitis-B virus (HBV)-antigen-specific T cell receptor (TCR) (LioCyx-M) as…
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Adult, Liver Cell Carcinoma
- Trial name
- NCT05195294
- Testing
- LioCyx-M, Lenvatinib
- Volunteers
- 55 people
- Sponsor
- Lion TCR Pte. Ltd.
BCLC Stage C Hepatocellular Carcinoma, Chemotherapy Effect
Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
This is a multi-center randomized phase III clinical study of first-line intravenous FOLFOX plus Camrelizumab and apatinib versus HAIC-FOLFOX plus Camrelizumab and apatinib for BCLC C stage hepatocellular carcinoma.
- Trial name
- NCT06172205
- Testing
- intravenous FOLFOX7 plus Camrelizumab and apatinib, HAIC-FOLFOX plus Camrelizumab and apatinib
- Where
- China
- Volunteers
- 262 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hepatocellular Carcinoma
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours…
- Trial name
- RHEA-1 (NCT06795022)
- Testing
- AZD9793 Intravenous (IV) monotherapy, AZD9793 Subcutaneous (SC) monotherapy
- Where
- 21 sites in United States, China and 5 more
- Volunteers
- 304 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma
β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
This study is a prospective, randomized controlled study on nutritional support and metabolic regulation. It assesses the safety, compliance, and improvement of metabolic/physical-related indicators when using β-alanine within…
- Trial name
- NCT07317414
- Testing
- Atezolizumab combined with bevacizumab combined with β- alanine, Atezolizumab combined with bevacizumab
- Where
- 3 sites in China
- Volunteers
- 158 people
- Sponsor
- Peking Union Medical College Hospital